Psychedelic treatments for mental health conditions pose challenges for informed consent

Seybert, Carolina; Cotovio, Gonçalo; Madeira, Luís; Ricou, Miguel; Pires, Ana Matos; Oliveira-Maia, AJ

doi:https://doi.org/10.1038/s41591-023-02378-5

Utilize este identificador para referenciar este registo: http://hdl.handle.net/10362/155905

Título:	Psychedelic treatments for mental health conditions pose challenges for informed consent
Autor:	Seybert, Carolina Cotovio, Gonçalo Madeira, Luís Ricou, Miguel Pires, Ana Matos Oliveira-Maia, AJ
Palavras-chave:	Biochemistry, Genetics and Molecular Biology(all) SDG 3 - Good Health and Well-being
Data:	Set-2023
Descrição:	Funding Information: C.S. received payment from the European Monitoring Centre for Drugs and Drug Addiction. A.M.P. received payment or honoraria from Janssen and Lundbeck and participated in advisory boards for Janssen and Angelini. A.J.O.-M. was the national coordinator for Portugal of trials for treatment-resistant depression of psilocybin, sponsored by Compass Pathways, Ltd (EudraCT number 2017-003288-36), and of esketamine, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019-002992-33); received payment or honoraria from MSD, Neurolite AG, Janssen and the European Monitoring Centre for Drugs and Drug Addiction; participated in advisory boards for Janssen and Angelini; and is the recipient of a grant from Schuhfried GmBH. The remaining authors declare no competing interests. Funding Information: We thank C. E. Fisher and J. Taborda da Gama for comments on an initial version of this manuscript. This work was supported by grant PTDC/MED-NEU/31331/2017 from the Fundação para a Ciência e Tecnologia to C.S., G.C. and A.J.O.-M. A.J.O.-M. received other grants from the Fundação para Ciência e Tecnologia (PTDC/SAU-NUT/3507/2021; PTDC/MED-NEU/1552/2021) and the Fundação para Ciência e Tecnologia and FEDER (PTDC/MED-NEU/30845/2017_LISBOA-01-0145-FEDER-030845; PTDC/MEC-PSQ/30302/2017_LISBOA-01-0145-FEDER-30302), a Starting Grant from the European Research Council (grant agreement no. 950357) and grants from the European Union’s Horizon 2020 research and innovation program (H2020‑SC1‑2017‑CNECT‑2‑777167‑ΒΟUNCE; H2020‑SC1‑DTH‑2019‑875358‑FAITH) and the European Joint Programme in Rare Diseases (Joint Translational Call 2019) through the Fundação para Ciência e Tecnologia (EJPRD/0001/2020).
Peer review:	yes
URI:	http://hdl.handle.net/10362/155905
DOI:	https://doi.org/10.1038/s41591-023-02378-5
ISSN:	1078-8956
Aparece nas colecções:	NMS - Artigos em revista internacional com arbitragem científica

Ficheiros deste registo:

Ficheiro	Descrição	Tamanho	Formato
s41591_023_02378_5.pdf		1,03 MB	Adobe PDF	Ver/Abrir

Mostrar registo em formato completo Dê a sua opinião sobre este registo.